|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
Hughes Syndrome, the Antiphospholipid Syndrome: A New Chapter in Neurology
aDepartment of Rheumatology, Homerton University Hospital, London, United Kingdom bLupus Research Unit, The Rayne Institute, St. Thomas' Hospital, London, United Kingdom
Address for correspondence: Graham R.V. Hughes, M.D., F.R.C.P., Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH, United Kingdom. Voice: +44-0-207-188-3570; fax: +44-0-207-620-2658. graham.hughes{at}kcl.ac.uk
The importance of cerebral disease in patients with the antiphospholipid (Hughes) syndrome (APS) is now becoming more widely recognized. The range of neuropsychiatric manifestations of APS is comprehensive and includes focal symptoms attributable to lesions in a specific area of the brain as well as diffuse or global dysfunction. Patients with APS frequently present with strokes and transient ischemic attacks, but a wide spectrum of other neurologic features, also including nonthrombotic neurological syndromes, has been described in association with the presence of antiphospholipid antibodies. In this review, we attempt to highlight the large variety of the neurological features of APS.
Key Words: central nervous system • cerebral ischemia • thrombosis • MRI • antiphospholipid antibodies • anticardiolipin antibodies • lupus anticoagulant This article has been cited by other articles:
| |||||||||||||||||||||||||||||
 |
 |
